Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 1 September 2000:
Vol. 289. no. 5484, pp. 1508 - 1514
DOI: 10.1126/science.289.5484.1508
Prev | Table of Contents | Next

Review

Therapeutic Approaches to Bone Diseases

Gideon A. Rodan,1* T. John Martin2dagger

The strength and integrity of our bones depends on maintaining a delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts. As we age or as a result of disease, this delicate balancing act becomes tipped in favor of osteoclasts so that bone resorption exceeds bone formation, rendering bones brittle and prone to fracture. A better understanding of the biology of osteoclasts and osteoblasts is providing opportunities for developing therapeutics to treat diseases of bone. Drugs that inhibit the formation or activity of osteoclasts are valuable for treating osteoporosis, Paget's disease, and inflammation of bone associated with rheumatoid arthritis or periodontal disease. Far less attention has been paid to promoting bone formation with, for example, growth factors or hormones, an approach that would be a valuable adjunct therapy for patients receiving inhibitors of bone resorption.

1 Merck Research Laboratories, West Point, PA 19486, USA.
2 St. Vincent's Institute of Medical Research, Melbourne 3065, Australia.
*   To whom correspondence should be addressed. E-mail: gideon_rodan{at}merck.com

dagger    Visiting Research Scholar at Lilly Research Laboratories, Indianapolis, IN 46285, USA.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Oxytocin Controls Differentiation of Human Mesenchymal Stem Cells and Reverses Osteoporosis.
C. Elabd, A. Basillais, H. Beaupied, V. Breuil, N. Wagner, M. Scheideler, L.-E. Zaragosi, F. Massiera, E. Lemichez, Z. Trajanoski, et al. (2008)
Stem Cells 26, 2399-2407
   Abstract »    Full Text »    PDF »
Translational medicine: cancer pain mechanisms and management.
A. Delaney, S. M. Fleetwood-Walker, L. A. Colvin, and M. Fallon (2008)
Br. J. Anaesth. 101, 87-94
   Abstract »    Full Text »    PDF »
Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease.
A. E. Kearns, S. Khosla, and P. J. Kostenuik (2008)
Endocr. Rev. 29, 155-192
   Abstract »    Full Text »    PDF »
Novel Pro-survival Functions of the Kruppel-like Transcription Factor Egr2 in Promotion of Macrophage Colony-stimulating Factor-mediated Osteoclast Survival Downstream of the MEK/ERK Pathway.
E. W. Bradley, M. M. Ruan, and M. J. Oursler (2008)
J. Biol. Chem. 283, 8055-8064
   Abstract »    Full Text »    PDF »
Wnt/beta-Catenin Signaling Is a Component of Osteoblastic Bone Cell Early Responses to Load-bearing and Requires Estrogen Receptor {alpha}.
V. J. Armstrong, M. Muzylak, A. Sunters, G. Zaman, L. K. Saxon, J. S. Price, and L. E. Lanyon (2007)
J. Biol. Chem. 282, 20715-20727
   Abstract »    Full Text »    PDF »
MITF and PU.1 Recruit p38 MAPK and NFATc1 to Target Genes during Osteoclast Differentiation.
S. M. Sharma, A. Bronisz, R. Hu, K. Patel, K. C. Mansky, S. Sif, and M. C. Ostrowski (2007)
J. Biol. Chem. 282, 15921-15929
   Abstract »    Full Text »    PDF »
Bisphosphonates as Inhibitors of Trypanosoma cruzi Hexokinase: KINETIC AND METABOLIC STUDIES.
C. E. Sanz-Rodriguez, J. L. Concepcion, S. Pekerar, E. Oldfield, and J. A. Urbina (2007)
J. Biol. Chem. 282, 12377-12387
   Abstract »    Full Text »    PDF »
Osteopontin deficiency enhances anabolic action of EP4 agonist at a sub-optimal dose in bone.
N. Kato, K. Kitahara, S. R Rittling, K. Nakashima, D. T Denhardt, H. Kurosawa, Y. Ezura, and M. Noda (2007)
J. Endocrinol. 193, 171-182
   Abstract »    Full Text »    PDF »
Chemokines in Oral Inflammatory Diseases: Apical Periodontitis and Periodontal Disease.
T.A. Silva, G.P. Garlet, S.Y. Fukada, J.S. Silva, and F.Q. Cunha (2007)
J. Dent. Res. 86, 306-319
   Abstract »    Full Text »    PDF »
Inhibin A Is an Endocrine Stimulator of Bone Mass and Strength.
D. S. Perrien, N. S. Akel, P. K. Edwards, A. A. Carver, M. S. Bendre, F. L. Swain, R. A. Skinner, W. R. Hogue, K. M. Nicks, T. M. Pierson, et al. (2007)
Endocrinology 148, 1654-1665
   Abstract »    Full Text »    PDF »
Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis.
E. Lopez-Granados, S. T. Temmerman, L. Wu, J. C. Reynolds, D. Follmann, S. Liu, D. L. Nelson, F. Rauch, and A. Jain (2007)
PNAS 104, 5056-5061
   Abstract »    Full Text »    PDF »
Attenuation of Bone Mass and Increase of Osteoclast Formation in Decoy Receptor 3 Transgenic Mice.
C.-H. Tang, T.-L. Hsu, W.-W. Lin, M.-Z. Lai, R.-S. Yang, S.-L. Hsieh, and W.-M. Fu (2007)
J. Biol. Chem. 282, 2346-2354
   Abstract »    Full Text »    PDF »
A p38{alpha} Selective Mitogen-Activated Protein Kinase Inhibitor Prevents Periodontal Bone Loss.
K. L. Kirkwood, F. Li, J. E. Rogers, J. Otremba, D. D. Coatney, J. M. Kreider, N. J. D'Silva, S. Chakravarty, S. Dugar, L. S. Higgins, et al. (2007)
J. Pharmacol. Exp. Ther. 320, 56-63
   Abstract »    Full Text »    PDF »
Bone Mineral Density Response to Caloric Restriction-Induced Weight Loss or Exercise-Induced Weight Loss: A Randomized Controlled Trial.
D. T. Villareal, L. Fontana, E. P. Weiss, S. B. Racette, K. Steger-May, K. B. Schechtman, S. Klein, and J. O. Holloszy (2006)
Arch Intern Med 166, 2502-2510
   Abstract »    Full Text »    PDF »
Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.
M. M. Rahman, A. Bhattacharya, and G. Fernandes (2006)
J. Lipid Res. 47, 1739-1748
   Abstract »    Full Text »    PDF »
Farnesyl Diphosphate Synthase Is a Cytosolic Enzyme in Leishmania major Promastigotes and Its Overexpression Confers Resistance to Risedronate..
A. Ortiz-Gomez, C. Jimenez, A. M. Estevez, J. Carrero-Lerida, L. M. Ruiz-Perez, and D. Gonzalez-Pacanowska (2006)
Eukaryot. Cell 5, 1057-1064
   Abstract »    Full Text »    PDF »
Use of bisphosphonates to improve the durability of total joint replacements..
A. S. Shanbhag (2006)
J. Am. Acad. Ortho. Surg. 14, 215-225
   Abstract »    Full Text »    PDF »
Wnt signalling in osteoblasts regulates expression of the receptor activator of NF{kappa}B ligand and inhibits osteoclastogenesis in vitro.
G. J. Spencer, J. C. Utting, S. L. Etheridge, T. R. Arnett, and P. G. Genever (2006)
J. Cell Sci. 119, 1283-1296
   Abstract »    Full Text »    PDF »
Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts.
J.-T. Woo, M. Kawatani, M. Kato, T. Shinki, T. Yonezawa, N. Kanoh, H. Nakagawa, M. Takami, K. H. Lee, P. H. Stern, et al. (2006)
PNAS 103, 4729-4734
   Abstract »    Full Text »    PDF »
Bone Biology and the Clinical Implications for Osteoporosis.
P. A Downey and M. I Siegel (2006)
Physical Therapy 86, 77-91
   Abstract »    Full Text »    PDF »
{alpha}-Lipoic Acid Inhibits Inflammatory Bone Resorption by Suppressing Prostaglandin E2 Synthesis.
H. Ha, J.-H. Lee, H.-N. Kim, H.-M. Kim, H. B. Kwak, S. Lee, H.-H. Kim, and Z. H. Lee (2006)
J. Immunol. 176, 111-117
   Abstract »    Full Text »    PDF »
Parathyroid hormone: past and present.
J. T Potts (2005)
J. Endocrinol. 187, 311-325
   Abstract »    Full Text »    PDF »
Acute Neuropathic Joint Disease: A medical emergency?.
A. L. Tan, A. Greenstein, S. J. Jarrett, and D. McGonagle (2005)
Diabetes Care 28, 2962-2964
   Full Text »    PDF »
Osthole-Mediated Cell Differentiation through Bone Morphogenetic Protein-2/p38 and Extracellular Signal-Regulated Kinase 1/2 Pathway in Human Osteoblast Cells.
P.-L. Kuo, Y.-L. Hsu, C.-H. Chang, and J.-K. Chang (2005)
J. Pharmacol. Exp. Ther. 314, 1290-1299
   Abstract »    Full Text »    PDF »
Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis.
S. Y. Han, N. K. Lee, K. H. Kim, I. W. Jang, M. Yim, J. H. Kim, W. J. Lee, and S. Y. Lee (2005)
Blood 106, 1240-1245
   Abstract »    Full Text »    PDF »
Prostaglandin EP4 receptor agonist augments fixation of hydroxyapatite-coated implants in a rat model of osteoporosis.
K. Hayashi, A. Fotovati, S. A. Ali, K. Oda, H. Oida, and M. Naito (2005)
J Bone Joint Surg Br 87-B, 1150-1156
   Abstract »    Full Text »    PDF »
IL-4 Inhibits Bone-Resorbing Activity of Mature Osteoclasts by Affecting NF-{kappa}B and Ca2+ Signaling.
L. S. Mangashetti, S. M. Khapli, and M. R. Wani (2005)
J. Immunol. 175, 917-925
   Abstract »    Full Text »    PDF »
Sustained Osteomalacia of Long Bones Despite Major Improvement in Other Hypophosphatasia-Related Mineral Deficits in Tissue Nonspecific Alkaline Phosphatase/Nucleotide Pyrophosphatase Phosphodiesterase 1 Double-Deficient Mice.
H. C. Anderson, D. Harmey, N. P. Camacho, R. Garimella, J. B. Sipe, S. Tague, X. Bi, K. Johnson, R. Terkeltaub, and J. L. Millan (2005)
Am. J. Pathol. 166, 1711-1720
   Abstract »    Full Text »    PDF »
Suppressors of Cytokine Signaling-1 and -3 Regulate Osteoclastogenesis in the Presence of Inflammatory Cytokines.
M. Ohishi, Y. Matsumura, D. Aki, R. Mashima, K. Taniguchi, T. Kobayashi, T. Kukita, Y. Iwamoto, and A. Yoshimura (2005)
J. Immunol. 174, 3024-3031
   Abstract »    Full Text »    PDF »
Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification.
T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qiao, M. C. Fishbein, R. C. Detrano, P. K. Shah, and T. B. Rajavashisth (2004)
Endocr. Rev. 25, 629-672
   Abstract »    Full Text »    PDF »
The Significance of Vasoactive Intestinal Peptide in Immunomodulation.
M. Delgado, D. Pozo, and D. Ganea (2004)
Pharmacol. Rev. 56, 249-290
   Abstract »    Full Text »    PDF »
Curcumin (Diferuloylmethane) Inhibits Receptor Activator of NF-{kappa}B Ligand-Induced NF-{kappa}B Activation in Osteoclast Precursors and Suppresses Osteoclastogenesis.
A. C. Bharti, Y. Takada, and B. B. Aggarwal (2004)
J. Immunol. 172, 5940-5947
   Abstract »    Full Text »    PDF »
Estrogen Deficiency Accelerates Murine Autoimmune Arthritis Associated with Receptor Activator of Nuclear Factor-{kappa}B Ligand-Mediated Osteoclastogenesis.
T. Yoneda, N. Ishimaru, R. Arakaki, M. Kobayashi, T. Izawa, K. Moriyama, and Y. Hayashi (2004)
Endocrinology 145, 2384-2391
   Abstract »    Full Text »    PDF »
Tob deficiency superenhances osteoblastic activity after ovariectomy to block estrogen deficiency-induced osteoporosis.
M. Usui, Y. Yoshida, K. Tsuji, K. Oikawa, K. Miyazono, I. Ishikawa, T. Yamamoto, A. Nifuji, and M. Noda (2004)
PNAS 101, 6653-6658
   Abstract »    Full Text »    PDF »
CMRF-35-Like Molecule-1, a Novel Mouse Myeloid Receptor, Can Inhibit Osteoclast Formation.
D.-H. Chung, M. B. Humphrey, M. C. Nakamura, D. G. Ginzinger, W. E. Seaman, and M. R. Daws (2003)
J. Immunol. 171, 6541-6548
   Abstract »    Full Text »    PDF »
HIV Envelope gp120-mediated Regulation of Osteoclastogenesis via Receptor Activator of Nuclear Factor {kappa}B Ligand (RANKL) Secretion and Its Modulation by Certain HIV Protease Inhibitors through Interferon-{gamma}/RANKL Cross-talk.
J. M. Fakruddin and J. Laurence (2003)
J. Biol. Chem. 278, 48251-48258
   Abstract »    Full Text »    PDF »
Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation.
S. Kim, T. Koga, M. Isobe, B. E. Kern, T. Yokochi, Y. E. Chin, G. Karsenty, T. Taniguchi, and H. Takayanagi (2003)
Genes & Dev. 17, 1979-1991
   Abstract »    Full Text »    PDF »
Lytic Bone Lesions in Human Neuroblastoma Xenograft Involve Osteoclast Recruitment and Are Inhibited by Bisphosphonate.
Y. Sohara, H. Shimada, M. Scadeng, H. Pollack, S. Yamada, W. Ye, C. P. Reynolds, and Y. A. DeClerck (2003)
Cancer Res. 63, 3026-3031
   Abstract »    Full Text »    PDF »
Impaired Osteoclast Formation in Bone Marrow Cultures of Fgf2 Null Mice in Response to Parathyroid Hormone.
Y. Okada, A. Montero, X. Zhang, T. Sobue, J. Lorenzo, T. Doetschman, J. D. Coffin, and M. M. Hurley (2003)
J. Biol. Chem. 278, 21258-21266
   Abstract »    Full Text »    PDF »
Farnesyl Pyrophosphate Synthase Is an Essential Enzyme in Trypanosoma brucei. IN VITRO RNA INTERFERENCE AND IN VIVO INHIBITION STUDIES.
A. Montalvetti, A. Fernandez, J. M. Sanders, S. Ghosh, E. Van Brussel, E. Oldfield, and R. Docampo (2003)
J. Biol. Chem. 278, 17075-17083
   Abstract »    Full Text »    PDF »
Positive Regulation of Endochondral Cartilage Growth by Perichondrial and Periosteal Calcitonin.
D. L. Di Nino and T. F. Linsenmayer (2003)
Endocrinology 144, 1979-1983
   Abstract »    Full Text »    PDF »
Increased Bone Mass Is a Part of the Generalized Lymphoproliferative Disorder Phenotype in the Mouse.
V. Katavic, I. K. Lukic, N. Kovacic, D. Grcevic, J. A. Lorenzo, and A. Marusic (2003)
J. Immunol. 170, 1540-1547
   Abstract »    Full Text »    PDF »
A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1-34)] with Alendronate in Postmenopausal Women with Osteoporosis.
J.-J. Body, G. A. Gaich, W. H. Scheele, P. M. Kulkarni, P. D. Miller, A. Peretz, R. K. Dore, R. Correa-Rotter, A. Papaioannou, D. C. Cumming, et al. (2002)
J. Clin. Endocrinol. Metab. 87, 4528-4535
   Abstract »    Full Text »    PDF »
Abnormal Bone Architecture and Biomechanical Properties with Near-Lifetime Treatment of Rats with PTH.
M. Sato, J. Vahle, A. Schmidt, M. Westmore, S. Smith, E. Rowley, and L. Y. Ma (2002)
Endocrinology 143, 3230-3242
   Abstract »    Full Text »    PDF »
Inhibition of Nanobacteria by Antimicrobial Drugs as Measured by a Modified Microdilution Method.
N. Ciftcioglu, M. A. Miller-Hjelle, J. T. Hjelle, and E. O. Kajander (2002)
Antimicrob. Agents Chemother. 46, 2077-2086
   Abstract »    Full Text »    PDF »
Sequential Treatment with Basic Fibroblast Growth Factor and PTH Is More Efficacious than Treatment with PTH Alone for Increasing Vertebral Bone Mass and Strength in Osteopenic Ovariectomized Rats.
U. T. Iwaniec, Li. Mosekilde, N. G. Mitova-Caneva, J. S. Thomsen, and T. J. Wronski (2002)
Endocrinology 143, 2515-2526
   Abstract »    Full Text »    PDF »
Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation.
K. Yoshida, H. Oida, T. Kobayashi, T. Maruyama, M. Tanaka, T. Katayama, K. Yamaguchi, E. Segi, T. Tsuboyama, M. Matsushita, et al. (2002)
PNAS 99, 4580-4585
   Abstract »    Full Text »    PDF »
Rationale for the role of osteoclast-like cells in arterial calcification.
T. M. DOHERTY, H. UZUI, L. A. FITZPATRICK, P. V. TRIPATHI, C. R. DUNSTAN, K. ASOTRA, and T. B. RAJAVASHISTH (2002)
FASEB J 16, 577-582
   Abstract »    Full Text »    PDF »
ER{alpha} Gene Expression in Human Primary Osteoblasts: Evidence for the Expression of Two Receptor Proteins.
S. Denger, G. Reid, M. Kos, G. Flouriot, D. Parsch, H. Brand, K. S. Korach, V. Sonntag-Buck, and F. Gannon (2001)
Mol. Endocrinol. 15, 2064-2077
   Abstract »    Full Text »    PDF »
Androgens Suppress Osteoclast Formation Induced by RANKL and Macrophage-Colony Stimulating Factor.
D. M. Huber, A. C. Bendixen, P. Pathrose, S. Srivastava, K. M. Dienger, N. K. Shevde, and J. W. Pike (2001)
Endocrinology 142, 3800-3808
   Abstract »    Full Text »    PDF »
Severe Osteopenia in a Young Boy With Kostmann's Congenital Neutropenia Treated With Granulocyte Colony-Stimulating Factor: Suggested Therapeutic Approach.
R. V. Sekhar, S. Culbert, W. K. Hoots, M. J. Klein, H. Zietz, and R. Vassilopoulou-Sellin (2001)
Pediatrics 108, e54-54
   Abstract »    Full Text »    PDF »
Osteoprotegerin Diminishes Advanced Bone Cancer Pain.
N. M. Luger, P. Honore, M. A. C. Sabino, M. J. Schwei, S. D. Rogers, D. B. Mach, D. R. Clohisy, and P. W. Mantyh (2001)
Cancer Res. 61, 4038-4047
   Abstract »    Full Text »
Bone Resorption by Osteoclasts.
S. L. Teitelbaum (2000)
Science 289, 1504-1508
   Abstract »    Full Text »
Domain-specific Mutations of a Transforming Growth Factor (TGF)-beta 1 Latency-associated Peptide Cause Camurati-Engelmann Disease Because of the Formation of a Constitutively Active Form of TGF-beta 1.
T. Saito, A. Kinoshita, K.-i. Yoshiura, Y. Makita, K. Wakui, K. Honke, N. Niikawa, and N. Taniguchi (2001)
J. Biol. Chem. 276, 11469-11472
   Abstract »    Full Text »    PDF »
Evaluating the Signal Transduction Mechanism of the Parathyroid Hormone 1 Receptor. EFFECT OF RECEPTOR-G-PROTEIN INTERACTION ON THE LIGAND BINDING MECHANISM AND RECEPTOR CONFORMATION.
S. R. J. Hoare, T. J. Gardella, and T. B. Usdin (2001)
J. Biol. Chem. 276, 7741-7753
   Abstract »    Full Text »    PDF »
Bisphosphonates Are Potent Inhibitors of Trypanosoma cruzi Farnesyl Pyrophosphate Synthase.
A. Montalvetti, B. N. Bailey, M. B. Martin, G. W. Severin, E. Oldfield, and R. Docampo (2001)
J. Biol. Chem. 276, 33930-33937
   Abstract »    Full Text »    PDF »
Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation.
K. Yoshida, H. Oida, T. Kobayashi, T. Maruyama, M. Tanaka, T. Katayama, K. Yamaguchi, E. Segi, T. Tsuboyama, M. Matsushita, et al. (2002)
PNAS 99, 4580-4585
   Abstract »    Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)